A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Table 4

The relationship between different variables and DFS for breast cancer patients with nonpCR.

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
Age (≤49 vs. >49)	1.05 (0.73-1.5)	0.813
Position (left vs. right)	1.08 (0.75-1.56)	0.679
Menopause (no vs. yes)	1.24 (0.86-1.78)	0.255
Parturition (0 vs. 1)	0.46 (0.28-0.76)	0.002	0.45 (0.27-0.76)	0.003
Parturition (0 vs. 2)	0.77 (0.44-1.34)	0.352	0.73 (0.41-1.28)	0.2683
DFS.INPS (≤0.4896 vs. >0.4896)	2.22 (1.5-3.27)	<0.001	1.84 (1.20-2.83)	0.005
DFS.L (≤1.39 vs. >1.39)	0.63 (0.39-1.03)	0.067
DFS.N (≤5.47 vs. >5.47)	1.87 (1.2-2.91)	0.006	1.47 (0.90-2.41)	0.122
DFS.M (≤0.36 vs. >0.36)	1.59 (1.06-2.39)	0.026	1.18 (0.76-1.83)	0.459
DFS.HB (≤132 vs. >132)	0.74 (0.52-1.07)	0.110
DFS.P (≤304 vs. >304)	1.38 (0.86-2.21)	0.185
DFS.ALB (≤43 vs. >43)	1.43 (0.95-2.15)	0.091
DFS.GLOB (≤28.5 vs. >28.5)	1.40 (0.94-2.1)	0.100
Clinical T stage (1 vs. 2)	0.75 (0.4-1.42)	0.377
Clinical T stage (1 vs. 3)	0.95 (0.47-1.93)	0.886
Clinical T stage (1 vs. 4)	2.80 (0.78-10.05)	0.115
Clinical N stage (0 vs. 1)	2.37 (0.54-10.51)	0.256
Clinical N stage (0 vs. 2)	2.18 (0.54-8.92)	0.276
Clinical N stage (0 vs. 3)	3.41 (0.82-14.2)	0.092
Clinical TNM stage (II vs. III)	1.27 (0.71-2.27)	0.413
Molecular subtype (luminal A vs. B)	1.72 (0.96-3.09)	0.066
Molecular subtype (luminal A vs. HER-2 OE)	1.67 (0.86-3.23)	0.127
Molecular subtype (luminal A vs. TNBC)	1.37 (0.68-2.75)	0.378
ER (negative vs. positive)	1.00 (0.69-1.46)	0.980
PR (negative vs. positive)	0.91 (0.63-1.3)	0.592
HER-2 (negative vs. low expression)	1.18 (0.75-1.83)	0.476
HER-2 (negative vs. positive)	1.34 (0.87-2.08)	0.189
Ki-67 (<20% vs. ≥20%)	1.31 (0.9-1.91)	0.152
P53 (negative vs. positive)	0.96 (0.64-1.46)	0.860
Cycle (≤4 vs. >4)	1.18 (0.82-1.71)	0.371